Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
Kirstine Brown-FrandsenScott S EmersonDarren K McGuireThomas R PieberNeil R PoulterRichard E PratleyBernard ZinmanMattis F RantheRandi GrønMartin LangeAlan C MosesPetra ÖrsyJohn B Busenull nullPublished in: Diabetes, obesity & metabolism (2019)
Use of liraglutide was associated with significantly lower risk of MACE and death in patients with type 2 diabetes and high cardiovascular risk using basal insulin.